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Impact of Pretreatment Neutrophil Count on Chemotherapy
Administration and Toxicity in Dogs with Lymphoma Treated with
CHOP Chemotherapy
Q. Fournier , J.-C. Serra, I. Handel, and J. Lawrence
Background: Prechemotherapy absolute neutrophil count (ANC) cutoﬀs are arbitrary and vary across institutions and
clinicians. Similarly, subjective guidelines are utilized for the administration of prophylactic antibiotics in neutropenic dogs.
Objectives: To evaluate the impact of various ANC cutoﬀs on chemotherapy administration in dogs with lymphoma
treated with CHOP chemotherapy and to determine whether an association between prechemotherapy ANC and subsequent
toxicity exists. The secondary objective was to evaluate a currently used ANC cutoﬀ to indicate prescription of prophylactic
antibiotics.
Animals: Dogs diagnosed with lymphoma treated with CHOP chemotherapy (n = 64).
Methods: Six hundred and ﬁfteen ANCs were stratiﬁed into 6 classes. The 3 ANC cutoﬀs 1.5 9 103/lL, 2.0 9 103/lL,
and 2.5 9 103/lL were assessed. The presence of an association between prechemotherapy ANC class and toxicity was
determined. Afebrile neutropenic dogs with ANC <1.5 9 103/lL but above the criteria for prophylactic antibiotics were
evaluated.
Results: Chemotherapy was not administered in 7% of visits with an ANC cutoﬀ of 1.5 9 103/lL; chemotherapy would
not have been administered in 10% and 16% of visits with an ANC cutoﬀ of 2.0 9 103/lL or 2.5 9 103/lL, respectively.
There was no association among the 3 lower prechemotherapy ANC classes and toxicity. All dogs with ANC 0.75–1.5 9 103/lL
recovered spontaneously without medical intervention.
Conclusion and Clinical Importance: The number of dose delays was minimized with a prechemotherapy ANC cutoﬀ of
1.5 9 103/lL, and the prechemotherapy ANC class 1.5–1.99 9 103/lL was not associated with an increased toxicity. Further
investigation of an ANC cutoﬀ near 0.75 9 103/lL in which to prescribe prophylactic antibiotics is indicated.
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Chemotherapy in companion animals with cancertypically is administered at maximally tolerated
doses and should allow good quality of life throughout
treatment.1–3 Chemotherapy drugs can be associated
with a broad spectrum of toxicities, notably bone mar-
row suppression.4,5 Before each chemotherapy adminis-
tration, CBC is recommended to assess absolute
neutrophil count (ANC) and determine whether
chemotherapy administration can proceed as scheduled.
The ANC criteria for chemotherapy administration are
arbitrary and vary across institutions and clinicians.
Published ANC cutoﬀs in veterinary medicine range
from 1.5 9 103/lL to 2.5 9 103/lL with 2.0 9 103/lL
being most commonly reported.6–15 Management of
chemotherapy-induced neutropenia in dogs is largely
based on clinical experience although some standards
have been published.4,5,16
In non-Hodgkin’s lymphoma in humans, a decrease
in chemotherapy relative dose intensity (RDI) has been
associated with poorer outcome.17–21 In dogs with lym-
phoma treated with a multidrug chemotherapy proto-
col, several studies suggested chemotherapy-induced
neutropenia prolonged ﬁrst remission duration.22,23 It
remains unclear, however, if RDI is directly associated
with outcome in these dogs.7,23 Because RDI is
impacted by dose delays and dose reductions,
prechemotherapy ANC cutoﬀs likely are clinically rele-
vant. Determination of an optimal ANC cutoﬀ may
increase chemotherapy RDI and subsequently improve
remission duration in dogs with lymphoma.
As with prechemotherapy ANC cutoﬀs, multiple
ANC cutoﬀs that prompt administration of prophy-
lactic antibiotics have been used.6,9–11 Published cutoﬀs
vary from 1.0 9 103/lL to 2.5 9 103/lL.6,9–11 Given
recognition of increasing antimicrobial antibiotic
resistance,24 the use of prophylactic antibiotic should be
considered carefully. There is little evidence to support
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a speciﬁc ANC that increases the risk of sepsis, how-
ever, it is possible that dogs, as is the case in humans,
have a low risk of sepsis if the ANC remains
≥0.5 9 103/lL.25,26 Guidelines in the United States rec-
ommend the use of antibacterial prophylaxis for human
chemotherapy patients expected to have <0.1 9 103
neutrophils/lL for >7 days, unless other factors increase
the risk for complications.27 At our institution, a
prechemotherapy ANC cutoﬀ of 1.5 9 103/lL is uti-
lized routinely and prophylactic antibiotics are adminis-
tered when postchemotherapy ANC falls below
0.75 9 103/lL.
Given the lack of literature in support of strong rec-
ommendations for establishment of a prechemotherapy
ANC cutoﬀ and guidelines for usage of prophylactic
antibiotics, institutional guidelines for chemotherapy for
lymphoma in dogs at our institution were assessed to
determine whether guideline alterations were indicated.
The primary objectives were 2-fold: (1) to compare the
proportion of dogs that would require chemotherapy
treatment delay if various ANC cutoﬀs were imple-
mented; and (2) to determine whether an association
exists between prechemotherapy ANC and subsequent
chemotherapy toxicity with a standardized chemother-
apy protocol. A secondary objective was to determine
whether the ANC cutoﬀ used at our institution to indi-
cate prescription of prophylactic antibiotics resulted in
the need for hospitalization and supportive care.
Materials and Methods
Dogs
All dogs included in the study were presented to an academic
veterinary specialty oncology service between January 2013 and
January 2016. Dogs were eligible if they had a cytological diagno-
sis consistent with lymphoma or histological diagnosis consistent
with intermediate to high-grade lymphoma by a board-certiﬁed
clinical pathologist or anatomic pathologist, respectively. Treat-
ment-na€ıve or relapsed dogs with lymphoma were eligible if they
were prescribed a standardized 19-week multi-agent chemotherapy
protocol. Relapsed dogs must have received the same protocol at
diagnosis as treatment-na€ıve dogs. Dogs were excluded if they had
an incomplete medical record, were receiving systemic antibiotics
for an infectious process (eg, pyoderma), received only 1 dose of
chemotherapy, or presented with neutropenia. Overt pancytopenia
and neutropenia at diagnosis were excluded because prechemother-
apy ANC did not determine whether or not chemotherapy admin-
istration would proceed. Investigations that were recommended
for all dogs included CBC with blood smear evaluation, serum
biochemistry, urinalysis, thoracic radiographs, abdominal radio-
graphs and ultrasound examination with ﬁne needle aspiration
cytology of abnormal ﬁndings, immunophenotyping, and bone
marrow evaluation. Minimal investigations to permit chemother-
apy included CBC and serum biochemistry.
Chemotherapy
A standardized 19-week multi-agent chemotherapy protocol,
consisting of 4 cycles of cyclophosphamide, doxorubicin, vin-
cristine, and prednisolone (CHOP), was prescribed to all dogs.28
Vincristine was administered IV at 0.7 mg/m2 on the ﬁrst and third
weeks of each cycle, cyclophosphamide was administered PO at
250 mg/m2 on the second week of each cycle, and doxorubicin was
administered IV at 30 mg/m2 for dogs ≥10 kg and 25 mg/m2 for
dogs <10 kg on the fourth week of each cycle. Mitoxantrone was
substituted for doxorubicin if dilated cardiomyopathy was present
or if deemed appropriate by the attending clinician and cardiologist.
CBCs were performed before chemotherapy and 7 days after
chemotherapy administration. Additional CBCs were performed
when clinically indicated. If prechemotherapy ANC was
<1.5 9 103/lL, a treatment delay of 2–7 days followed by a 10%
dose reduction in the drug previously administered was instituted to
maintain dose intensity (DI) for the remaining protocol. For dox-
orubicin or mitoxantrone, if the nadir ANC was ≥0.75 9 103/lL, a
subsequent dose reduction was not performed. Chemotherapy
adverse events were graded according to the Veterinary Cooperative
Oncology Group guidelines (VCOG-CTCAE) version 1.1,29 with
dose-limiting toxicity (DLT) deﬁned as grade 4 neutropenia and
≥ grade 3 gastrointestinal toxicity. Assessment of toxicity was per-
formed using CBC data, a weekly quality of life questionnaire com-
pleted by the owner, and weekly physical examinations.
Chemotherapy dosage reduction of 10% was instituted after the
occurrence of DLT. Chemotherapy dosage could be re-escalated by
5% at the clinician’s discretion. Strict antibiotic usage guidelines
were instituted. Afebrile neutropenic dogs with ANC <0.75 9 103/
lL were prescribed prophylactic trimethoprim–sulfonamide (15 mg/
kg PO q12h) for 3–4 days. For dogs sensitive to trimethoprim–
sulfonamide, enroﬂoxacin (10 mg/kg PO q24h) was prescribed.
The choice of these antibiotics was based on current human litera-
ture,30–34 previous veterinary recommendations,4,5,26 and guidelines
later published as part of a consensus by the American College of
Veterinary Internal Medicine.35 Febrile neutropenia was deﬁned as
chemotherapy-induced neutropenia (ANC <2.5 9 103/lL) in con-
junction with fever (rectal temperature >39.2°C).36 Febrile neu-
tropenic dogs were managed with inpatient supportive care. All
febrile neutropenic patients had (at minimum) 3-view thoracic
radiographs, urinalysis, and urine culture to evaluate for infection
before institution of antibiotics.
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Stratiﬁcation
All CBCs were reviewed, while dogs were on chemotherapy. To
address the primary objectives, 3 speciﬁc ANC cutoﬀs values for
chemotherapy administration were assessed: 1.5 9 103/lL (cutoﬀ
1), 2.0 9 103/lL (cutoﬀ 2), and 2.5 9 103/lL (cutoﬀ 3). For anal-
ysis, prechemotherapy ANC values then were stratiﬁed into 6
classes to evaluate the impact of the ANC. To assess the 3 previ-
ously deﬁned ANC cutoﬀs for chemotherapy administration,
neutropenia was stratiﬁed into class C1: 1.5–1.99 9 103/lL, C2:
2.0–2.49 9 103/lL, C3: 2.5–2.99 9 103/lL, and C4:
3.0–3.49 9 103/lL. The reference interval also was represented by
the class C5: 3.5–12.0 9 103/lL and neutrophilia by the class C6:
>12.0 9 103/lL. To address the secondary objective,
postchemotherapy ANC values were divided as follows:
0.75–0.99 9 103/lL and 1.0–1.49 9 103/lL to stratify dogs and
evaluate classes for the likelihood of requiring inpatient care.
Statistical Analysis
Kruskal–Wallis tests and multiple comparisons by the Bonfer-
roni adjustment method were used to test the diﬀerence in
chemotherapy-induced toxicity among prechemotherapy ANC
classes. Dunnett-type multiple comparison tests for proportion
were employed to compare the proportions of chemotherapy treat-
ments associated with hospitalization, DLT, and febrile neutrope-
nia among prechemotherapy ANC classes.37 The inﬂuence of
additional factors on chemotherapy-induced neutropenia was
assessed by ordinal logistic regression. These factors included
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initial body weight, initial body condition score as deﬁned by the
World Small Animal Veterinary Association,38 prechemotherapy
neutrophil : lymphocyte ratio, and number of CHOP protocols
administered. Statistical analyses were performed by commercially
available statistics software (Minitaba), under the guidance of a
statistician (IH). A P-value <0.05 was considered statistically sig-
niﬁcant for all analyses. Graphs were made by commercially avail-
able graphic software (GraphPad Prismb).
Results
Dogs
Seventy-ﬁve dogs initially met the inclusion criteria.
Eleven dogs were excluded: 2 dogs for incomplete medi-
cal record information, 5 dogs for having received only
1 dose of chemotherapy, 3 dogs for having pancytope-
nia with neutropenia at presentation, and 1 dog for
having a concurrent prostatic abscess requiring systemic
antibiotic treatment. Therefore, 64 dogs were included
in the study. Clinical characteristics of dogs with lym-
phoma were similar to those previously reported
(Table 1).6–11,23,39 Eight dogs were fully staged with
bone marrow aspirate, whereas all dogs were minimally
assessed with CBC and serum biochemistry. Although
most of the dogs had multicentric lymphoma, the ana-
tomic form was variable (Table 2).
Chemotherapy Protocol Modiﬁcations
Fourteen dogs had alterations to their prescribed
chemotherapy protocols. Six dogs received L-asparagi-
nase at the time of initial vincristine because of clinical
illness at presentation. One dog received vinblastine
instead of vincristine after presumptive vincristine-
induced peripheral neuropathy that occurred after 5
doses. Three dogs received chlorambucil substituted for
cyclophosphamide; 2 dogs developed sterile hemor-
rhagic cystitis (SHC) after 1 and 2 doses of cyclophos-
phamide, and 1 dog because of owner concern for the
risk of developing SHC. Five dogs received mitox-
antrone instead of doxorubicin; 3 dogs were switched
after receiving a cumulative doxorubicin dosage of
180 mg/m2 (after relapse and institution of a second
CHOP protocol after completion of the ﬁrst protocol),
1 dog because of clinical concern for increased risk of
doxorubicin-induced cardiac toxicity, and 1 dog because
of grade III diarrhea. Cyclophosphamide was utilized as
the initial drug in 2 dogs; in 1 dog, venous access could
not be obtained for the ﬁrst dose, whereas the other
dog was given cyclophosphamide because of clinician
preference.
Chemotherapy Administration
A total of 736 CBCs were reviewed for the study to
obtain ANCs. Among them, 615 were prechemotherapy
CBCs (including 70 before ﬁrst CHOP administration
[64] or subsequent CHOP protocol [6]), and 108 were
CBCs performed 7 days after doxorubicin or mitox-
antrone administration. Thirteen CBCs were performed
at various intervals because of clinical illness and pre-
sumed chemotherapy toxicity. Chemotherapy was
administered after evaluation of CBCs in 569 instances,
whereas dose delay occurred 46 times because of neu-
tropenia below the cutoﬀ of 1.5 9 103 neutrophils/lL
(38) or because of clinical illness (8). All 38 episodes of
dose delays due to neutropenia resulted in a 10% dose
reduction at the subsequent administration of the drug
that induced neutropenia, but in 5 dogs (3 cyclophos-
phamide, 2 vincristine), the dose was subsequently esca-
lated by 5% once in 3 dogs and twice in 2 dogs,
without associated DLT.
Assessment of Prechemotherapy ANC Cutoﬀs on
Chemotherapy Administration
To evaluate the potential clinical impact of altering
the ANC cutoﬀ for chemotherapy administration,
prechemotherapy ANCs were stratiﬁed as described for
analysis into classes, excluding the 70 ANCs from ﬁrst
chemotherapy administration. Overall, 93% of the
ANCs were above the standard clinical cutoﬀ of
1.5 9 103 neutrophils/lL (cutoﬀ 1) established for rou-
tine practice at our institution. When cutoﬀ 1 was uti-
lized, 7% (38/545) of chemotherapy administrations
were delayed. Had cutoﬀ 2 been applied, 10% (54/545)
of chemotherapy administrations would have been
delayed in this particular set of dogs. Had cutoﬀ 3 been
used, 16% (85/545) of chemotherapy administrations
would have been delayed. Of the 64 dogs in the study,
22 dogs (34%) were dose-delayed at least once using
Table 1. Characteristics of the 64 dogs included in the
study.
Parameter
Age (years)
Median (range) 7.4 (1.6–13.3)
Sex
Male 35 (54%)
Female 29 (46%)
Body weight (kg)
Median (range) 26.7 (6.2–75.2)
Breeds
Labrador Retriever 12 (18%)
Border Collie 5 (7%)
Boxer 5 (7%)
Cocker Spaniel 3 (4%)
West Highland White Terrier 3 (4%)
Crossbreed 8 (12%)
Other breeds (≤2) 31 (48%)
Table 2. Anatomic form of lymphoma in 64 dogs.
Anatomic Form Number (%)
Multicentric 43 (67.2%)
Mediastinal 8 (12.5%)
Gastrointestinal 6 (9.4%)
Hepato-splenic 4 (6.3%)
Cutaneous nonepitheliotropic 2 (3.1%)
Nasal 1 (1.5%)
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cutoﬀ 1. If ANC cutoﬀ 2 or cutoﬀ 3 had been used to
permit chemotherapy administration, 24 (38%) and 32
(50%) of dogs would have had at least 1 dose delay,
respectively.
Assessment of Prechemotherapy ANC Cutoﬀs on
Chemotherapy Toxicity
Of the 569 chemotherapy administrations over the
duration of the study, there were 344 (60%) docu-
mented instances of toxicity (Table 3). Of the 64 dogs
in the study, 53 dogs (82%) experienced toxicity and
multiple episodes of toxicity were common. No signiﬁ-
cant diﬀerence was observed in the overall incidence of
chemotherapy-induced toxicity among prechemotherapy
ANC classes. There were 26 (5%) documented instances
of DLT (Table 3). No signiﬁcant diﬀerence was
observed in the incidence of DLT among prechemother-
apy ANC classes.
Thirty incidences in which hospitalization was neces-
sary secondary to chemotherapy toxicity were recorded
and represented 5% of all chemotherapy administra-
tions (Table 3). Twenty-two dogs (34%) were hospital-
ized during chemotherapy; 17 dogs were hospitalized
once, 3 dogs twice, and 1 dog each 3 or 4 times. Con-
sidering the 17 dogs hospitalized once, the cause of hos-
pitalization was febrile neutropenia for 7 dogs, grade 2
and grade 3 gastrointestinal toxicity for 2 and 6 dogs,
respectively, and aspiration pneumonia for 1 dog. No 2
dogs were hospitalized for the same series of adverse
events. Of the 3 dogs hospitalized twice, causes included
2 episodes of grade 2 gastrointestinal toxicity, grade 3
gastrointestinal toxicity and febrile neutropenia, and
grade 3 gastrointestinal toxicity and SHC. The dog that
was hospitalized on 3 occasions developed febrile neu-
tropenia twice and grade 3 gastrointestinal toxicity. The
dog hospitalized 4 times developed 3 episodes of grade
3 gastrointestinal toxicity and 1 episode of grade 2 gas-
trointestinal toxicity. One dog died in hospital after
developing aspiration pneumonia and respiratory dis-
tress. All remaining dogs were discharged after a med-
ian hospital stay of 1 day (range, 1–7 days). No
signiﬁcant diﬀerence was observed in the incidence of
hospitalization in dogs stratiﬁed by prechemotherapy
ANC class.
Of 569 chemotherapy treatments administered, 194
neutropenic episodes (34%) were documented (Fig 1).
Postchemotherapy neutropenia was more likely to occur
in ANC class C3 compared to C5 (P < 0.001) and C6
(P = 0.002). However, postchemotherapy neutropenia
in class C3 was mostly represented by grade 1 neutrope-
nia (18 episodes), and only 6 postchemotherapy neu-
tropenic episodes were ≥ grade 2. When only
postchemotherapy neutropenia ≥ grade 2 was evaluated,
no signiﬁcant diﬀerence was observed between the ANC
class C3 compared to C5 (P = 0.256) and C6
(P = 0.922). No signiﬁcant diﬀerences were identiﬁed
when other classes were compared in post hoc analysis.
In particular, no signiﬁcant diﬀerence in postchemother-
apy neutropenia was observed when the ANC classes
C1 and C2 were compared to C4, C5, or C6 (P > 0.05).
Also, no signiﬁcant diﬀerence was found among the
ANC classes C1, C2, and C3 (P = 0.22).
Overall, 10 episodes of febrile neutropenia occurred,
representing 1.8% of all chemotherapy administrations
(Table 3). Five dogs had grade IV neutropenia, 4 had
grade III neutropenia, and 1 had grade I neutropenia at
presentation. Drugs administered before febrile neu-
tropenia included the following: doxorubicin (8), vin-
cristine (1), and cyclophosphamide (1). Most (6)
instances of febrile neutropenia occurred in the ﬁrst
cycle of CHOP, whereas 1 occurred in the second cycle
and 3 occurred in the third cycle. Similarly, most (5)
instances occurred at the initial administration of the
drug, whereas 2 cases occurred after the second drug
exposure and 3 occurred after a third exposure. No sig-
niﬁcant diﬀerence was identiﬁed in the incidence of feb-
rile neutropenia in dogs stratiﬁed by prechemotherapy
ANC class.
Of chemotherapy treatments administered, 204
(35.6%) were associated with nonhematologic toxicities.
When stratiﬁed by prechemotherapy ANC class, no sig-
niﬁcant diﬀerence was found in the occurrence of non-
hematologic toxicity among the ANC classes
(P = 0.603; Fig 2).
Assessment of ANC Cutoﬀ for Prophylactic
Antibiotics Prescription
Thirty-eight chemotherapy dose delays (7%) occurred
because of prechemotherapy neutropenia, whereas dogs
were afebrile and clinically well. In 6 of the dose delays
(16%), dogs had prechemotherapy ANC between 0.75
and 0.99 9 103/lL, and in 22 instances (58%), dogs
had prechemotherapy ANC between 1.0 and
1.49 9 103/lL. None of the dogs received prophylactic
Table 3. The number of chemotherapy administrations and toxicities associated with each prechemotherapy ANC
class (C).
PreChemotherapy
ANC Classes C1 C2 C3 C4 C5 C6
ANC (9103/lL) 1.5–1.99 2.0–2.49 2.5–2.99 3.0–3.49 3.5–12.0 >12.0
Chemotherapy administration 16 31 41 41 384 56
Toxicity (any grade) 8 25 31 26 226 28
Dose-limiting toxicity (DLT) 2 0 3 5 11 5
Febrile neutropenia 1 0 1 3 3 2
Hospitalization 2 0 3 5 13 7
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antibiotics, and all recovered well without supportive
care. In 10 of the 38 dose delays (26%), dogs had
prechemotherapy ANC <0.75 9 103/lL and received
prophylactic antibiotics PO. None received additional
supportive care.
Assessment of Additional Factors Aﬀecting
Chemotherapy-Induced Neutropenia
The prechemotherapy neutrophil : lymphocyte count
ratio varied from 0.17 to 98.5, with a median of 5.43.
Ordinal regression showed no evidence of an associa-
tion between prechemotherapy neutrophil : lymphocyte
count ratio and the occurrence of neutropenia
(P = 0.822).
Fifty-eight dogs were treated with 1 CHOP
chemotherapy protocol, 4 dogs were prescribed a sec-
ond CHOP chemotherapy protocol, and 1 dog under-
went 4 CHOP chemotherapy protocols. Ordinal
regression showed no evidence of an association
between the number of CHOP protocols and the occur-
rence of neutropenia (P = 0.492).
The initial body weight varied from 6.2 to 75.2 kg,
with a median of 26.7 kg. Ordinal regression showed no
evidence of an association between initial body weight
and occurrence of neutropenia (P = 0.063). Initial body
condition score varied from 3/9 to 8/9, with a median
of 5/9. No signiﬁcant association was observed between
the initial body condition score and development of
neutropenia (P = 0.822).
Discussion
Maintaining good quality of life during chemotherapy
is a goal for the majority of owners of cancer-bearing
companion animals. Diﬀerent strategies to alleviate
adverse eﬀects of chemotherapy may be employed and
typically are dependent on the clinician, the individual
pet owner’s expectations. Supportive care including pro-
phylactic medication, dose modiﬁcations (dose delay,
dose reduction, or both), drug substitution, and ulti-
mately cessation of chemotherapy are options consid-
ered when treating pets and are similar to strategies
employed in humans.4,25,33,40 In human patients,
chemotherapy dose delays and dose reductions may
negatively aﬀect outcome, and a concerted eﬀort is
made to maintain DI.41 General guidelines for
chemotherapy dose modiﬁcations have been suggested
in an attempt to standardize chemotherapy administra-
tion and minimize potential impact on patient out-
come.25,33,40,42 For example, the South East London
Cancer Network recommends a chemotherapy dose
delay after a prechemotherapy ANC <1.0 9 103/lL
with a 25% dose reduction in subsequent treatments if
the delay was >1 week.40 Likewise, in veterinary oncol-
ogy, chemotherapy dose delay followed by a 20% dose
reduction has been recommended when the
prechemotherapy ANC <1.5 9 103/lL,5 but there are
little data to support this reduction. Nonetheless, ANC
cutoﬀ values of 2.5 9 103/lL and 2.0 9 103/lL con-
tinue to be used.6–8,12
Given the lack of evidence supporting speciﬁc recom-
mendations for prechemotherapy ANC cutoﬀ values in
clinical practice, the potential impact of the most com-
monly used ANC cutoﬀs (1.5 9 103/lL, 2.0 9 103/lL
and 2.5 9 103/lL) was assessed using a subset of dogs
subjected to the lowest cutoﬀ. As expected, the higher
the ANC cutoﬀ, the higher the number of dose delays
and potential dose reductions. Importantly, no signiﬁ-
cant diﬀerence was observed in the development of toxi-
city in dogs when their ANC decreased between 1.5 and
2.0 9 103/lL compared to higher cutoﬀ values. A
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Fig 1. Incidence of postchemotherapy neutropenia after adminis-
tration of 569 chemotherapy treatments, stratiﬁed by
prechemotherapy ANC classes. Postchemotherapy neutropenia
was graded according to the VCOG-CTCAE guidelines version
1.1.29 Prechemotherapy ANC was stratiﬁed in 6 classes: class C1)
1.5–1.99 9 103/lL (N = 16), class C2) 2.0–2.49 9 103/lL
(N = 31), class C3) 2.5–2.99 9 103/lL (N = 41), class C4) 3.0–
3.49 9 103/lL (N = 41), class C5) 3.5–12.0 9 103/lL (N = 384),
and class C6) > 12.0 9 103/lL (N = 56). There was a signiﬁcant
diﬀerence between the prechemotherapy ANC classes C3 and C5
(P < 0.001), and C3 and C6 (P = 0.002).
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Fig 2. Incidence of postchemotherapy nonhematologic toxicity
after administration of 569 chemotherapy treatments, stratiﬁed by
prechemotherapy ANC classes. Postchemotherapy nonhematologic
toxicity (constitutional or gastrointestinal) was graded according
to the VCOG-CTCAE guidelines version 1.1.29 Prechemotherapy
ANC was stratiﬁed in 6 classes: class C1) 1.5–1.99 9 103/lL
(N = 16), class C2) 2.0–2.49 9 103/lL (N = 31), class C3) 2.5–
2.99 9 103/lL (N = 41), class C4) 3.0–3.49 9 103/lL (N = 41),
class C5) 3.5–12.0 9 103/lL (N = 384), and class C6) >
12.0 9 103/lL (N = 56). There was no signiﬁcant diﬀerence
between the prechemotherapy ANC classes (P = 0.603).
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signiﬁcant diﬀerence in the development of neutropenia
was noted when ANC class C3 was compared to either
C5 or C6, but no signiﬁcant increased risk of neutrope-
nia was found between C1 and C2 when compared to
C5 and C6. As it is diﬃcult to identify a reasonable bio-
logical explanation for ANC class C3 to be the only
class associated with a higher likelihood of neutropenia
than for classes with normal neutrophil count or neu-
trophilia, and this ﬁnding likely represents type I error.
Also, most of the postchemotherapy neutropenic epi-
sodes in ANC class C3 were grade 1 neutropenia, and
no signiﬁcant diﬀerence in the development of ≥ grade
2 neutropenia was found between ANC class C3 when
compared to C5 or C6. Because grade 1 neutropenia
does not result in chemotherapy dose delay or dose
reduction, the statistical signiﬁcance in the development
of neutropenia between the ANC class C3 compared to
C5 and C6 is of questionable clinical relevance.
No signiﬁcant association was identiﬁed between the
likelihood of neutropenia and additional factors
investigated. Physiologic, corticosteroid-induced, and
inﬂammatory leukocytoses all can aﬀect the neu-
trophil : lymphocyte ratio, and all can be present in
cancer-bearing dogs.43 The neutrophil : lymphocyte
ratio previously has been shown to be of clinical value
in patients with cancer,44 but it was not associated with
the likelihood of neutropenia in our study. The impact
of the number of CHOP protocols on chemotherapy-
induced neutropenia was assessed to evaluate for possi-
ble cumulative bone marrow toxicity. Although we did
not ﬁnd a signiﬁcant change in the likelihood of neu-
tropenia with previous CHOP protocols in our study, it
is possible that inclusion of other drugs such as lomus-
tine in an induction protocol may alter the risk of
cumulative myelosuppression. The impact of body
weight on chemotherapy-induced neutropenia also was
assessed, because lower body weight previously has
been associated with development of sepsis, but no sig-
niﬁcant association between weight at diagnosis and
neutropenia was identiﬁed.45 However, dosage reduc-
tions are integral to the CHOP protocol in that dogs
<10 kg already receive decreased chemotherapy dosage
for some drugs (ie, doxorubicin is dosed at 25 mg/m2
instead of 30 mg/m2 for dogs < 10 kg). Vincristine and
cyclophosphamide were dosed similarly across body
weights and body condition scores. Because body condi-
tion score previously was associated with chemotherapy
toxicity and the eﬀect of cachexia and obesity on
chemotherapy dosing is controversial in humans, we
also evaluated if body condition score was associated
with neutropenia.46 Body condition score, however, was
not assigned by the same individual, a factor that may
have aﬀected the ﬁndings.
Using the standard ANC cutoﬀ of 1.5 9 103/lL,
34% of dogs experienced at least 1 dose delay because
of prechemotherapy neutropenia. However, had the cut-
oﬀ been 2.5 9 103/lL (and all CBC data remained the
same), approximately 50% of dogs would have experi-
enced a delay and potentially dose reduction, thus eﬀec-
tively decreasing the RDI. Lowering the ANC cutoﬀ to
the lowest tolerable level may avoid unnecessary dose
reductions and maintain DI throughout treatment. This
concept is diﬃcult to evaluate in clinical practice, espe-
cially because clinician preference often guides practice
and standards can be challenging to implement. Our
study presents hypothetical results because it assumes
that all dogs would have identical CBC data regardless
of the timing of chemotherapy administration, dosage
administered, or both (which likely would have been
altered with higher ANC cutoﬀ values for intervention).
Although it would be ideal to randomize dogs to vari-
able ANC class levels so as to permit treatment and
subsequently assess changes in the rate of toxicity,
remission status, and remission duration, this approach
is impractical if clinicians ﬁrmly believe the cutoﬀ being
used in their practice is correct. Multi-institutional data
could be combined whereby clinicians and practices use
diﬀerent criteria for treatment, but other protocols such
as percentage of dose reduction, antibiotic selection,
and duration of treatment may be more diﬃcult to
institute.
The term DI is used to deﬁne the drug dose delivered
per time unit and is expressed as mg/m2 per week.
Treatment delays and dose reductions therefore
decrease DI. To characterize modiﬁcations of
chemotherapy schemes, the concept of RDI, which
reﬂects delivered DI divided by standard DI, has been
introduced.47 A decrease in RDI in human patients with
diﬀuse large B-cell lymphoma who are treated with
rituximab-CHOP (R-CHOP) is associated with poorer
outcome.18,20,21 In 1 study in which dogs with lym-
phoma were treated with multidrug chemotherapy and
half-body irradiation, development of grade III or IV
neutropenia was positively associated with remission
duration, but RDI was not associated with outcome.23
In another study, dogs experiencing neutropenia during
the ﬁrst 9 weeks of CHOP-based treatment had pro-
longed ﬁrst remission duration.22 Notably, 76.9% of the
neutropenia episodes in this study were grade I.22
Treatment delays also have been associated with
improved outcome.7,39 In both of these studies, treat-
ments were delayed if the prechemotherapy ANC was
<2.0 9 103/lL and the authors postulated that
improved survival was attributed to neutropenic epi-
sodes. These studies indirectly support the notion that
prechemotherapy ANC <2.0 9 103/lL may be associ-
ated with improved outcome measures.5,23,31 Compara-
tively, in human oncology, it has been noted since the
1970s that neutropenia is associated with improved out-
come measures in several tumor types and chemother-
apy protocols.48 Taken together, these data emphasize
the need to investigate prechemotherapy ANC in dogs
and whether a cutoﬀ such as 1.5 9 103/lL improves
remission duration. However, the exact role of RDI in
veterinary medicine is unclear. Even in human oncol-
ogy, RDI may have diﬀerent impacts across tumor
types,49 and possible artifacts might complicate its
interpretation.50
Most chemotherapy dosages are based on the
patient’s body surface area, which does not correlate
well with drug pharmacokinetics.51–54 Because DI is
related to chemotherapy dosage, RDI may not be
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clinically important in dogs with lymphoma.52,53,55,56
However, a higher proportion of dogs than necessary
may receive a suboptimal chemotherapy dosage after a
dose delay if the neutrophil cutoﬀ is high, making it dif-
ﬁcult to assess the eﬀects of RDI. Bone marrow sup-
pression, and neutropenia in particular, may be
indicative of more eﬀective dosing. This hypothesis has,
in part, led to individualized pharmacokinetic dosing of
common chemotherapeutic drugs in human oncology,
and early studies have suggested a potential to decrease
toxicity and improve disease-free intervals.57–60 Moni-
toring of neutrophil count as a barometer for
chemotherapy dosage and eﬃcacy is appealing because
of its simplicity and cost-eﬀectiveness in veterinary med-
icine. One dosing strategy that could be evaluated
would be dose escalation in each dog until achieving
the lowest safe prechemotherapy ANC. Determination
of a safe prechemotherapy ANC and its timing is chal-
lenging, but 1.5 9 103/lL, could be a starting point
based on our study. An alternative strategy might be to
use the neutrophil nadir as a target and to aim to
achieve an ANC of 0.75–1.0 9 103/lL at the time of
expected nadir and maintain an ANC of at least
1.5 9 103/lL for subsequent chemotherapy administra-
tion. It is prudent before undertaking extensive study to
fully determine whether RDI, neutropenia, or both
impact remission duration. Although individualized
dosing is attractive and may provide a beneﬁt long-
term, it may be costly and time-consuming for some cli-
ents, particularly if more aggressive monitoring and
chemotherapy administration are undertaken.
Relative dose intensity may also be more heavily
dependent on some drugs in the CHOP protocol.
Indeed, a relative dose reduction in vincristine has been
associated with poorer outcome in human patients diag-
nosed with diﬀuse large B-cell lymphoma treated with
R-CHOP.19 In a recent study investigating the use of
25-week CHOP in dogs, the authors suggested a tempo-
ral relationship existed between relapse of lymphoma
and cyclophosphamide.61 Although further investigation
is necessary to conﬁrm this observation, eﬀorts could be
focused on improving DI of drugs considered most use-
ful for the disease. Results provided here suggest that
the severity of prechemotherapy neutropenia is not
necessarily associated with an increase in
postchemotherapy nonhematologic toxicity. Therefore,
individualization of chemotherapy dosage along with
optimization of RDI may improve remission status
without compromising the dog’s quality of life.
A secondary objective of our study was to provide an
audit of a current protocol for the management of neu-
tropenic dogs. Antibiotic resistance has become a sub-
stantial concern in both veterinary and human
medicine,24 and prophylactic antibiotic treatment should
be used thoughtfully, and only when deemed necessary.
In human medicine, the routine use of prophylactic
antibiotics typically is reserved for patients expected to
develop profound neutropenia, which is variably deﬁned
(≤0.1 9 103/lL to ≤0.5 9 103/lL). Most trials investi-
gating prophylactic antibiotics have been used in
patients receiving high-dose chemotherapy for
hematologic malignancies and have demonstrated a
decrease in mortality.39–41 Antibacterial prophylaxis
now is considered in the current National Institute for
Health and Care Excellence (NICE) guidelines for the
prevention of febrile neutropenia in people with acute
leukemias, stem cell transplants, or solid tumors when
neutropenia ≤0.5 9 103/lL is expected.42 When consid-
ering the risk of neutropenic sepsis, the severity and
duration of neutropenia are important, but other
factors such as tumor type, underlying immunologic
function, and potentially environmental exposure also
inﬂuence the risk of neutropenic sepsis.40,43,44 In
veterinary medicine, the neutrophil nadir is not known
for each animal although estimates are made to deter-
mine the timing of each CBC. An ANC cutoﬀ of
1.0 9 103/lL has been suggested to trigger the prescrip-
tion of prophylactic antibiotics in afebrile neutropenic
dogs but, as with prechemotherapy ANC values, there
is little evidence to support this guideline.4,5,16 Clinicians
may be reluctant to use a lower neutrophil cutoﬀ to
allow a margin of safety if the nadir neutrophil count
was not truly captured, or because they are less tolerant
of adverse chemotherapy events in pets than are their
counterparts in human medicine.
Ours is the ﬁrst study to suggest that an ANC cutoﬀ
as low as 0.75 9 103/lL to trigger prophylactic antibi-
otic prescription may be reasonable for clinical use. Six
dogs presented with afebrile grade 3 neutropenia at an
ANC nadir between 0.75 and 1.0 9 103/lL, and all
recovered spontaneously without need for intervention.
Further studies are necessary to determine whether this
cutoﬀ is reasonable as a standardized recommendation
in clinical practice.
Although the percentage of dogs that experienced
hospitalization (34%) in our study was higher than in
previous reports (9.8–11.5%),7,39 the overall incidence
of hospitalization was 5%, as previously reported.4,5
Upon evaluation of VCOG toxicity scores, actual scores
were similar to those previously reported.62,63 The rela-
tively higher rate of hospitalization may have resulted
from the fact that there is subjectivity about the need
for hospitalization, which may relate to the clinician
who evaluated the case, comfort level of the client, or
both. Notably, a similar proportion of dogs that devel-
oped ≥ grade 3 gastrointestinal toxicity was similar to
previous reports, and fewer dogs (38%) in our study
required dose reduction compared to previous reports
(54–62%).7,39 Because our neutrophil cutoﬀ was lower
than that of other reports, we may have had fewer dose
delays and fewer dose reductions may have occurred.
Similarly, the incidence of presumed SHC (3.1%) was
higher than expected despite the concurrent use of furo-
semide at the time of cyclophosphamide administration.
Although only 2 dogs developed presumptive SHC,
diagnosis was based on clinical signs, abdominal ultra-
sound examination, urinalysis, and negative bacterial
culture. In both dogs, presumed SHC resolved within
48 hours, similar to previous reports.64 Although the
assumption was made that both dogs developed
cyclophosphamide-induced SHC to avoid underestimat-
ing the risk of urinary toxicity, rapid resolution also
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may have been consistent with non-chemotherapy-asso-
ciated cystitis.
Our study had several limitations. Despite the 615
prechemotherapy CBCs collected for the study, there
were relatively low numbers of prechemotherapy CBCs
with an ANC within the lower classes (C1, C2, and
C3). This situation might have led to type II error in
the determination of an association between
prechemotherapy ANC classes and toxicity. However,
this ﬁnding further supports the contention that a
prechemotherapy ANC of 1.5 9 103/lL is not associ-
ated with a higher likelihood of neutropenia. Complete
blood counts were assessed at predetermined time
points in the protocol, unless clinical illness supported
an additional CBC. Because the timing of the neu-
trophil nadir likely is variable across dogs, the severity
of neutropenia may have been diﬀerent in some dogs. It
is diﬃcult to justify collecting serial (daily) CBC data in
dogs with lymphoma during a weekly chemotherapy
protocol given concerns about quality of life and poten-
tial occupational exposure, but that approach would be
necessary to more accurately capture neutropenic epi-
sodes. Not all dogs were fully staged with bone marrow
assessment, and missing bone marrow involvement
could have aﬀected the neutrophil counts. The lowest
ANC cutoﬀ evaluated for chemotherapy administration
(ie, 1.5 9 103/lL) was applied to all dogs in our study,
but the results obtained might have been diﬀerent if the
3 ANC cutoﬀs evaluated would have been applied in 3
diﬀerent groups of dogs. However, this was not per-
formed for ethical reasons, and our approach seemed
reasonable given that dogs received chemotherapy at
the lowest ANC cutoﬀ. The ANC classes were selected
arbitrarily based on other published reports in the vet-
erinary literature, and other stratiﬁcation schemes may
have altered results. Despite eﬀorts to standardize a
toxicity grading scale, grading of nonhematologic toxici-
ties was partially inﬂuenced by the observations of own-
ers. Owners also had an inﬂuence on the decision for
hospitalization because some owners were more averse
than others to managing toxicity at home. These limita-
tions are inherent to the VCOG-CTCAE criteria, which
do not deﬁne when medications or hospitalization are
indicated.29 Also, our study only assessed the use of
CHOP in dogs with intermediate to high-grade lym-
phoma and the results do not necessarily translate to
other protocols and tumor types.
Conclusions
In this population of dogs with lymphoma receiving
19-week CHOP chemotherapy, an ANC cutoﬀ of
1.5 9 103/lL for chemotherapy administration allowed
a higher number of dogs to receive scheduled treatment
when compared to other reported ANC cutoﬀs for
administration. Prechemotherapy ANC was not associ-
ated with the incidence of chemotherapy-induced toxic-
ity. It is necessary to determine whether alterations in
ANC cutoﬀ and improvements in RDI improve remis-
sion durations. Because there is concern for indiscrimi-
nate antibiotic use, it is also necessary to critically
evaluate current prescription policies. An ANC cutoﬀ
near 0.75 9 103/lL for prophylactic antibiotic usage
was well tolerated in this population of dogs, but future
studies will be necessary to determine whether this same
experience can be documented in a larger number of
dogs.
Footnotes
a Minitab 17 Statistical Software (2010). [Computer software].
State College, PA: Minitab, Inc. (www.minitab.com)
b GraphPad Prism version 7.00 for Windows, GraphPad Software,
La Jolla, CA, www.graphpad.com
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